Team:EPF Lausanne/Calendar/13 September 2013

From 2013.igem.org

(Difference between revisions)
 
(One intermediate revision not shown)
Line 10: Line 10:
''Innoculation of Bacteria with our constructs'' <BR>
''Innoculation of Bacteria with our constructs'' <BR>
-
-In order to characterize both the sensing and the effector plasmid I innoculated Bacteria in liquid LB cultures over-night.
+
-In order to characterize both the sensing and the effector plasmid I inoculated Bacteria in liquid LB cultures over-night.
<BR><BR>
<BR><BR>
Line 16: Line 16:
''Biotinylation''<BR>
''Biotinylation''<BR>
-
-We Biotinylated the two new nanoparticles batches.
+
-We biotinylated the two new nanoparticles batches.
<BR>
<BR>
-End of the anti-strepta resistance check (sample mix, use of strepatavidin beads and microscopy)
-End of the anti-strepta resistance check (sample mix, use of strepatavidin beads and microscopy)

Latest revision as of 22:22, 4 October 2013

Taxi.Coli: Smart Drug Delivery iGEM EPFL

Header

Cell Surface Display

Inverted Microscopy
- All our constructs (ISA,ISD,ISI and competent cells as negative control) were incubated 1hr with TexRed conjugate nanoparticles.
- Visualization under the microscope with a cy5 filter.

Sensing-Effector

Innoculation of Bacteria with our constructs
-In order to characterize both the sensing and the effector plasmid I inoculated Bacteria in liquid LB cultures over-night.

Nanoparticles

Biotinylation
-We biotinylated the two new nanoparticles batches.
-End of the anti-strepta resistance check (sample mix, use of strepatavidin beads and microscopy)

DSL Measurements
-We did DLS measurements of the new biotinylated nanoparticles (before dialysis).